

Clinical Trial Protocol

Iranian Registry of Clinical Trials

16 Sep 2026

Evaluation of the efficacy and safety of botulinum toxin type A injection with cross-linked hyaluronic acid in comparison with non cross-linked hyaluronic acid in the treatment of patients with icepick acne scar: A double blind controlled randomized clinical trial

Protocol summary

Study aim

Evaluation of the efficacy and side effects of botulinum toxin type A injection with cross linked hyaluronic acid in comparison with non cross linked hyaluronic acid in the treatment of icepick acne scar

Design

Clinical trial with two intervention groups, parallel, double-blind, randomized, phase 3 on 16 patients, randomized with sealed envelopes

Settings and conduct

For injection, botulinum toxin type A is diluted with normal saline and then, depending on the extent of the scar and the area being treated, each volume of Dysport is drawn into a 1 cc syringe, five times mixed and diluted with hyaluronic acid (cross linked or non cross linked). The patient does not know in which treatment group he is. The data are also evaluated by the patient himself and a blind dermatologist and finally the statistical specialist, who also does not know which drug combination was injected in each group, analyzes the results of the study.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Patients with icepick acne scars in the range of 18 to 40 years Exclusion criteria: active acne, inflammation or active infection of herpes at the procedure site, hemodynamic instability, taking anticoagulant or NSAID during the previous 48 hours and also patients with platelet dysfunction or thrombocytopenia, serious internal disease, comorbidity at the treatment site

Intervention groups

Group 1: Injection of botulinum toxin type A and cross linked hyaluronic acid, Group 2: Injection of botulinum toxin type A and non cross linked hyaluronic acid

Main outcome variables

Qualitative and quantitative severity of scar with

Visioface, The rate of improvement with Global Aesthetic Improvement Scale (GAIS)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210718051930N1**

Registration date: **2021-07-30, 1400/05/08**

Registration timing: **prospective**

Last update: **2021-07-30, 1400/05/08**

Update count: **0**

Registration date

2021-07-30, 1400/05/08

Registrant information

Name

Abbas Dehghani

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 31 5472 6066

Email address

dehghani.aba@iums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-09-06, 1400/06/15

Expected recruitment end date

2022-04-04, 1401/01/15

Actual recruitment start date

empty

Actual recruitment end date
empty

Trial completion date
empty

Scientific title
Evaluation of the efficacy and safety of botulinum toxin type A injection with cross-linked hyaluronic acid in comparison with non cross-linked hyaluronic acid in the treatment of patients with icepick acne scar: A double blind controlled randomized clinical trial

Public title
Comparison of the effect of combining botulinum toxin and cross-linked hyaluronic acid with non cross-linked hyaluronic acid in the treatment of icepick acne scar

Purpose
Treatment

Inclusion/Exclusion criteria
Inclusion criteria:
All patients with icepick acne scar in the range of 18 to 40 years Having informed consent to participate in the study Possibility to attend visit and follow-up sections
Exclusion criteria:
Active acne Inflammation or herpes simplex virus infection at the site of the procedure Taking anticoagulants or NSAIDs within 48 hours before and in patients with platelet dysfunction or thrombocytopenia Serious internal disease Accompanying disease at the treatment site

Age
From **18 years** old to **40 years** old

Gender
Both

Phase
3

Groups that have been masked

- Participant
- Outcome assessor
- Data analyser

Sample size
Target sample size: **16**

Randomization (investigator's opinion)
Randomized

Randomization description
After being selected by available method, patients are divided into two groups by simple randomization, so that among 16 sealed bags, one bag will be randomly selected for each patient. Each bag contains the letter a or b: a for the group receiving botulinum toxin type A and cross-linked hyaluronic acid and b for the group receiving botulinum toxin type A and non cross-linked hyaluronic acid.

Blinding (investigator's opinion)
Double blinded

Blinding description
For group a patients, a combination of botulinum toxin type A and cross-linked hyaluronic acid is injected once, and for group b patients, a combination of botulinum toxin type A and non cross-linked hyaluronic acid is

injected twice with a month interval. The patient does not know in which treatment group he is. In order to evaluate, in two groups, before treatment, 1 month later and then 3 and 6 months after one month follow-up, the severity of icepick scars is measured qualitatively and quantitatively by Visioface and also the rate of improvement with Global Aesthetic Improvement Scale (GAIS) is determined by the patient and a blind dermatologist. Finally, the statistician, who also does not know which drug combination was injected in each group, analyzes the results of the study.

Placebo
Not used

Assignment
Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Iran University of medical sciences
Street address
Hazrat Rasool Akram hospital, Mansoori avenue, Sattarkhan street, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
1445613131
Approval date
2021-07-03, 1400/04/12
Ethics committee reference number
IR.IUMS.FMD.REC.1400.255

Health conditions studied

1

Description of health condition studied
icepick acne scar patients
ICD-10 code
L70.0
ICD-10 code description
Acne vulgaris

Primary outcomes

1

Description
Qualitative intensity of scar
Timepoint
At the beginning of the study, 1 month later and then 3 and 6 months later

Method of measurement

Photography with Visioface

2

Description

Quantitative intensity of scar

Timepoint

At the beginning of the study, 1 month later and then 3 and 6 months later

Method of measurement

Determine the depth of the scar by photography with Visioface

3

Description

The rate of improvement in scar

Timepoint

1 month after starting treatment and then 3 and 6 months later

Method of measurement

according to Global Aesthetic Improvement Scale (GAIS)

Secondary outcomes

1

Description

Side effects

Timepoint

1 month after starting treatment and then 3 and 6 months later

Method of measurement

Clinical evaluation

Intervention groups

1

Description

Intervention group 1: For patients in this group, a combination of botulinum toxin type A and cross-linked hyaluronic acid is injected once. For injection, botulinum toxin type A: Dysport® (abobotulinumtoxinA) with 300 units/vial is dissolved with 2 cc of normal saline and then, depending on the extent of the scar and the treated area, each volume of Dysport is drawn in the BD lower lock syringe, is mixed and diluted five times with cross-link hyaluronic acid through the interface 30 times. So that each small line of BD syringe contains 0.6 units of Dysport (microbotax). Cross-link hyaluronic acid used has low G prime of the NEAUVIA 22mg or INTENCE / REOLOGY brand. This injection is performed after local anesthesia with XylaP cream for 45 minutes and then wiping it with an alcohol swab, with Gauge 27 mesotherapy needle and under the scars intradermally.

Category

Treatment - Drugs

2

Description

Intervention group 2: For patients in this group, a combination of botulinum toxin type A and non cross-linked hyaluronic acid is injected twice with 1 month interval. For injection, botulinum toxin type A: Dysport® (abobotulinumtoxinA) with 300 units/vial is dissolved with 2 cc of normal saline and then, depending on the extent of the scar and the treated area, each volume of Dysport is drawn in the BD lower lock syringe, is mixed and diluted five times with non cross-link hyaluronic acid through the interface 30 times. So that each small line of BD syringe contains 0.6 units of Dysport (microbotax). Non cross-link hyaluronic acid used has REVITACARE 532 CYTOCARE brand. This injection is performed after local anesthesia with XylaP cream for 45 minutes and then wiping it with an alcohol swab, with Gauge 30 mesotherapy needle and under the scars intradermally.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Hazrat Rasool Akram hospital

Full name of responsible person

Elham Behrangi

Street address

Hazrat Rasool Akram hospital, Mansoori avenue, Sattarkhan street, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1445613131

Phone

+98 21 6651 6001

Email

elham.behrangi@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Dr. Seyyed Abbas Motevallian

Street address

Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1449614535

Phone

+98 21 8670 2503

Email

research-m@iums.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Iran University of Medical Sciences

Proportion provided by this source

35

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Elham Behrangi

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Dermatology ward, Hazrat Rasool Akram hospital,
Niayesh avenue, Satarkhan street, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1445613131

Phone

+98 21 6651 7341

Email

elham.behrangi@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Elham Behrangi

Position

Associate professor

Latest degree

Specialist

Other areas of specialty/work

Dermatology

Street address

Dermatology ward, Hazrat Rasool Akram hospital,
Niayesh avenue, Satarkhan street, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1445613131

Phone

+98 21 6651 7341

Email

elham.behrangi@gmail.com

Person responsible for updating data

Contact

Name of organization / entity

Iran University of Medical Sciences

Full name of responsible person

Abbas Dehghani

Position

Resident

Latest degree

Medical doctor

Other areas of specialty/work

Dermatology

Street address

Dermatology ward, Hazrat Rasool Akram hospital,
Mansoori avenue, Sattarkhan street, Tehran, Iran

City

Tehran

Province

Tehran

Postal code

1445613131

Phone

+98 21 6435 2390

Fax

Email

dehghani.abs@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Not applicable